The introduction of medications that affect immune checkpoints, such as PD‐1/PD‐L1 checkpoint blockade, has improved the survival of patients with bladder cancer and lowered the adverse effects that patients had to tolerate with conventional methods [37, 38]. The gene discussed is CD274; the disease is urinary bladder carcinoma.